Zai Lab (NASDAQ:ZLAB) Posts Earnings Results, Beats Estimates By $0.18 EPS

Zai Lab (NASDAQ:ZLAB) posted its earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.18, Zacks reports. The company had revenue of $108.21 million for the quarter, compared to analysts’ expectations of $107.90 million. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%.

Here are the key takeaways from Zai Lab’s conference call:

• Zoci’s early first-line small cell lung cancer data were encouraging: In 33 evaluable patients, zoci plus atezolizumab produced an 81.8% confirmed response rate and estimated six-month progression-free survival of 81.9%, with grade 3 or higher zoci-related adverse events in 9.1%. The results are from a small early-stage study; Zai Lab plans a global phase III trial and is targeting a potential U.S. BLA submission in 2027.
• Zai Lab expects three registrational studies to be underway by year-end and anticipates two registrational readouts in 2027. For zoci, a potential accelerated-approval filing in second-line or later small cell lung cancer depends on the DLLEVATE interim analysis, while an epNEC filing would depend on forthcoming data and durability follow-up.
• China product revenue increased 2% sequentially, and the commercial business remained profitable. Management expects a return to year-over-year product revenue growth in 2027, citing potential NRDL access expansion and demand across priority brands; that outlook remains a company forecast.
• Zai Lab reported $659.7 million in cash at quarter-end and raised approximately $250 million in October. Management said stable R&D and SG&A expenses, operational efficiencies, and the financing support investment in its global pipeline.
• The company plans to present the first human data for its internally developed atopic dermatitis candidate ZL-1503 next week, with patient efficacy data and an IV-to-subcutaneous bridging study expected in 2027. Zai Lab is also advancing additional oncology and immunology assets, though these programs remain at earlier development stages.

Zai Lab Stock Performance

Zai Lab stock opened at $25.48 on Friday. The business’s 50-day simple moving average is $24.62 and its two-hundred day simple moving average is $21.06. Zai Lab has a fifty-two week low of $15.96 and a fifty-two week high of $27.50. The company has a market cap of $2.90 billion, a PE ratio of -14.23 and a beta of 0.77.

Key Stories Impacting Zai Lab

Here are the key news stories impacting Zai Lab this week:

• Positive Sentiment: Zai Lab reported a third-quarter loss of $0.41 per ADS, narrower than analysts’ expected loss of about $0.59. Revenue of $108.21 million also slightly exceeded the $107.90 million estimate, providing a near-term earnings surprise. Earnings Flash
• Positive Sentiment: Investors are also looking toward the pipeline: coverage highlighted the possibility of Zai Lab’s first U.S. drug filing and described 2027 as a pivotal year. Progress toward internally developed medicines could provide future growth catalysts, though outcomes remain uncertain. Zai Lab Q3 2026: Loss Narrows 27%, Pipeline Eyes First US Drug Filing UBS on Q3 performance and 2027
• Neutral Sentiment: UBS said third-quarter performance met expectations, framing the main investment focus as execution on the milestones ahead rather than a major change in near-term results. UBS analysis
• Negative Sentiment: Some earnings coverage said revenue declined and the reported quarterly loss widened, tempering the favorable comparison with analyst estimates. Sustained revenue growth and progress through the pipeline remain important to the outlook. Zai Lab Q3 Loss Widens, Revenue Declines

Insider Activity

In other news, Director William Lis sold 8,506 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total transaction of $212,650.00. Following the completion of the transaction, the director directly owned 41,931 shares of the company’s stock, valued at $1,048,275. This trade represents a 16.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 9,385 shares of company stock worth $235,145 over the last 90 days. 4.88% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Tuesday, October 6th. Citigroup raised their price target on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zai Lab has a consensus rating of “Moderate Buy” and an average target price of $37.25.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.